Department of Molecular Immunology

Laboratory of Antibody Engineering

Kulemzin Sergey
Head of the Laboratory

Staff: 
thomson_logo.gif scopus_logo.jpg Kulemzin Sergey head PhD (Biology) skulemzinatmcb [dot] nsc [dot] ru
thomson_logo.gif scopus_logo.jpg Guselnikov Sergey senior research fellow PhD (Biology) sguselnikovatmcb [dot] nsc [dot] ru
thomson_logo.gif scopus_logo.jpg Chikaev Anton research fellow PhD (Biology) chikaevatmcb [dot] nsc [dot] ru
thomson_logo.gif scopus_logo.jpg Belovezhets Tatiana junior research fellow   belovezhecatmcb [dot] nsc [dot] ru

Recent publications: 
  1. Belovezhets T, Kulemzin S, Volkova O, Najakshin A, Taranin A, Gorchakov A. Comparative pre-clinical analysis of CD20-specific CAR T cells encompassing 1F5-, Leu16-, and 2F2-based antigen-recognition moieties. (doi: 10.3390/ijms24043698) Int J Mol Sci 24(4): 3698, 2023

  2. Nushtaeva A, Ermakov M, Abdurakhmanova M, Troitskaya O, Belovezhets T, Varlamov M, Gayner T, Richter V, Koval O. “Pulsed hypoxia” gradually reprograms breast cancer fibroblasts into pro-tumorigenic cells via mesenchymal–epithelial transition. (doi: 10.3390/ijms24032494Int J Mol Sci 24(3): 2494, 2023

  3. Yusubalieva GM, Dashinimaev EB, Gorchakov AA, Kulemzin SV, Brovkina OA, Kalinkin AA, Vinokurov AG, Shirmanova MV, Taranin AV, Baklaushev VP. Enhanced natural killers with CISH and B2M gene knockouts reveal increased cytotoxicity in glioblastoma primary cultures. (doi: 10.1134/S0026893322050156) Mol Biology 56(5): 770-779, 2022

  4. Astakhova EA, Byazrova MG, Yusubalieva GM, Kulemzin SV, Kruglova NA, Prilipov AG, Baklaushev VP, Gorchakov AA, Taranin AV, Filatov AV. Functional profiling of in vitro reactivated memory B cells following natural SARS-CoV-2 infection and Gam-COVID-Vac vaccination. (doi: 10.3390/cells11131991) Cells 11(13): 1991, 2022

  5. Yuzhakova D, Kiseleva E, Shirmanova M, Shcheslavskiy V, Sachkova D, Snopova L, Bederina E, Lukina M, Dudenkova V, Yusubalieva G, Belovezhets T, Matvienko D, Baklaushev V. Highly invasive fluorescent/bioluminescent patient-derived orthotopic model of glioblastoma in mice. (doi: 10.3389/fonc.2022.897839) Front Oncol 12: 897839, 2022

  6. Kulemzin SV, Sergeeva MV, Baranov KO, Gorchakov AA, Guselnikov SV, Belovezhets TN, Volkova OY, Najakshin AM, Chikaev NA, Danilenko DM, Taranin AV. VH3-53/66-Class RBD-specific human monoclonal antibody iB20 displays cross-neutralizing activity against emerging SARS-CoV-2 lineages. (doi: 10.3390/jpm12060895) J Pers Med 12(6): 895, 2022

  7. Byazrova MG, Kulemzin SV, Astakhova EA, Belovezhets TN, Efimov GA, Chikaev AN, Kolotygin IO, Gorchakov AA, Taranin AV, Filatov AV. Memory B cells induced by Sputnik V vaccination produce SARS-CoV-2 neutralizing antibodies upon ex vivo restimulation. (doi: 10.3389/fimmu.2022.840707Front Immunol 13: 840707, 2022

  8. Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA, Esina TI, Zaykovskaya AV, Pyankov OV, Borisevich SS, Shelemba AA, Chikaev AN, Ilyichev AA. Comparative immunogenicity of the recombinant receptor-binding domain of protein S SARS-CoV-2 obtained in prokaryotic and mammalian expression systems. (doi: 10.3390/vaccines10010096Vaccines 10(1): 96, 2022

  9. Smirnov S, Petukhov A, Levchuk K, Kulemzin S, Staliarova A, Lepik K, Shuvalov O, Zaritskey A, Daks A, Fedorova O. Strategies to circumvent the side-effects of immunotherapy using allogeneic CAR-T cells and boost its efficacy: Results of recent clinical trials. (doi: 10.3389/fimmu.2021.780145Front Immunol 12: 780145, 2021

  10. Kulemzin S, Evsyukov I, Belovezhets T, Taranin A, Gorchakov A. Horses for courses in the era of CARs: Advancing CAR T and CAR NK cell therapies. (doi: 10.3390/jpm11111182J Pers Med 11(11): 1182, 2021

  11. Gorchakov AA, Kulemzin SV, Guselnikov SV, Baranov KO, Belovezhets TN, Mechetina LV, Volkova OYu, Najakshin AM, Chikaev NA, Chikaev AN, Solodkov PP, Larichev VF, Gulyaeva MA, Markhaev AG, Kononova YuV, Alekseyev AYu, Shestopalov AM, Yusubalieva GM, Klypa TV, Ivanov AV, Valuev-Elliston VT, Baklaushev VP, Taranin AV. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. (doi: 10.1038/s41421-021-00340-8Cell Discov 7: 96, 2021

  12. Smagina AS, Kulemzin SV, Yusubalieva GM, Kedrova AG, Sanzharov AE, Ivanov YV, Matvienko DA, Kalsin VA, Gorchakov AA, Baklaushev VP, Taranin AV. VAV1‚Äźoverexpressing YT cells display improved cytotoxicity against malignant cells. (doi: 10.1002/bab.2001Biotechnol Appl Biochem 68(4): 849-855, 2021

  13. Starostina EV, Sharabrin SV, Antropov DN, Stepanov GA, Shevelev GYu, Lemza AE, Rudometov AP, Borgoyakova MB, Rudometova NB, Marchenko VYu, Danilchenko NV, Chikaev AN, Bazhan SI, Ilyichev AA, Karpenko LI. Construction and immunogenicity of modified mRNA-vaccine variants encoding influenza virus antigens (doi: 10.3390/vaccines9050452Vaccines 9(5): 452, 2021

‚ÄčPublication before year 2021 see Laboratory of Immunogenetics

Selected talks: 
  1. Chikaev A. CD47/SIRPa blockers and CARs: together we stand. XII Raisa Gorbacheva Memorial International Symposium "Hematopoietic Stem Cell Transplantation. Gene and Cellular Therapy", 20-22 September 2018, St. Petersburg, Russia

  2. Belovezhets T. Quest for the optimal NK-cell line as a CAR carrier. XII Raisa Gorbacheva Memorial International Symposium "Hematopoietic Stem Cell Transplantation. Gene and Cellular Therapy", 20-22 September 2018, St. Petersburg, Russia

  3. Kulemzin S. Forging the Natural Killer with genome editing. XII Raisa Gorbacheva Memorial International Symposium "Hematopoietic Stem Cell Transplantation. Gene and Cellular Therapy", 20-22 September 2018, St. Petersburg, Russia

  4. Kulemzin SV. Generation of NK-cell lines with enhanced therapeutic potential. International congress “CRISPR-2018”, September 10-14, 2018, Novosibirsk, Russia

  5. Guselnikov S. Evolution of FcR- and KIR-like leukocyte receptors: from Teleostei to Mammalia. Eastern Great Lakes Molecular Evolution Meeting. Koffler Institute for Pharmacy Management, University of Toronto, 30 April 2005, Toronto, Canada